Print

RN Jobs >> Browse Articles >> Pharma

RN Jobs >> Browse Articles >> Politics / Government

Rate

Wyeth Sues FDA to Block Rival Generic Antibiotic

Wyeth Sues FDA to Block Rival Generic Antibiotic

Associated Press/AP Online

September 23, 2009

TRENTON, N.J. – Drugmaker Wyeth on Wednesday sued the Food and Drug Administration to block the sale of a generic rival to its intravenous antibiotic Zosyn, claiming the generic is not an equivalent product and could harm critically ill patients.

Madison, N.J.-based Wyeth filed a federal lawsuit against the FDA, seeking both a temporary restraining order and a preliminary injunction. The lawsuit seeks to prevent Orchid Chemicals & Pharmaceuticals Ltd. of Chennai, India, from selling a generic version of Zosyn that the FDA approved last week.

Wyeth’s head of global medical affairs, Joe Camardo, said patient safety is at stake and that Orchid’s product could lead to preventable medical errors.

“Over 2 million people get Zosyn in any given year,” Camardo told The Associated Press in an interview.

News Articles

Many are critically ill patients with very serious infections, he said. So hospital workers are rushing to set up an intravenous line to rapidly feed in both Zosyn and, often, a standard IV solution to boost blood volume and maintain blood pressure. The problem is that with an older formulation of Zosyn, which Wyeth claims is what Orchid will be selling, if the same IV line is used, Zosyn can mix with the intravenous solution and cause a chemical reaction that inactivates the antibiotic, limiting how much patients would get.

“They wouldn’t get the full dose,” Camardo said.

That could mean the patient doesn’t get enough antibiotic to stop the infection.

In addition, having two different versions of the same antibiotic on the market could cause confusion when hospital workers are rushing to save very ill patients, Camardo said.

Wyeth discontinued the old version in October 2005, when the FDA approved a newer version that adds two ingredients to prevent the harmful chemical reaction.

Zosyn has been on the market for at least a decade. Wyeth reported that sales of Zosyn and a second antibiotic called Tazocin last year together totaled $1.3 billion.

Camardo said that Wyeth several years ago filed what’s called a “citizen’s petition” with the FDA, a request asking the agency not to allow generic Zosyn because of the potential for problems. The citizen’s petition laid out Wyeth’s scientific arguments and contained similar statements of support from outside experts on medication errors and drug interactions and effects, he said.

But the FBI denied the citizen’s petition last Tuesday and then approved Orchid’s drug last Wednesday, Camardo said.


NursingLink School Finder

Save time in your search for a degree program. Use NursingLink's School Finder to locate schools online and in your area.


* In the event that we cannot find a program from one of our partner schools that matches your specific area of interest, we may show schools with similar or unrelated programs.